Latest Advances in Epilepsy Treatment - May 2026

Drug-Resistant Epilepsy & Brain Devices

A growing amount of data is supporting responsive neurostimulation (RNS) devices for people whose seizures are not controlled with medication. New long-term studies presented around the 2026 American Academy of Neurology meeting showed substantial seizure reduction with implanted systems like NeuroPace RNS. One post-approval study reported a median 82% seizure reduction at 3 years.

This is important because:

• Many patients plateau on antiseizure medications
• Neuromodulation is becoming more mainstream earlier in treatment
• Devices are increasingly using AI-like pattern detection for seizure interruption

AI & Seizure Detection Research

A new research dataset called “Seizure-Semiology-Suite” was released this week to help train AI systems to recognize seizure types from video and multimodal clinical data. Researchers reported that specialized AI models could classify epileptic vs. non-epileptic seizures with very high accuracy.

This could eventually improve:

• ER seizure triage
• Remote seizure monitoring
• Diagnostic support in underserved areas
• Wearable seizure alert systems

Wearable Monitoring Improvements

Empatica’s seizure monitoring ecosystem continues expanding. Their wearable epilepsy monitoring systems now integrate more advanced physiologic sensors and machine-learning-based seizure detection.

Wearables are becoming more useful for:

• nocturnal seizure detection
• seizure clustering analysis
• caregiver alerts
• long-term trend tracking

New Medication Targets

Researchers recently identified a new binding site on SV2A — the same epilepsy target used by medications like:

• Keppra
• Briviact

The discovery may help create next-generation antiseizure drugs with:

• fewer psychiatric side effects
• better seizure specificity
• improved drug resistance response

Ketogenic Diet Mechanism Breakthrough

Researchers at UVA recently identified more detail about why ketogenic diets can reduce seizures in medication-resistant epilepsy. They found receptor pathways that may eventually allow “keto-mimicking” drugs without requiring the restrictive diet itself.

That is significant because:

• keto diets are difficult to sustain
• GI side effects and nutritional issues are common
• a medication alternative could help pediatric and adult patients

Lamotrigine Safety Reassurance

A major Rutgers study found that Lamictal did not increase cardiac risk in older adults with epilepsy, despite prior FDA warnings.

That matters because many neurologists became cautious prescribing lamotrigine in people with heart conditions after the 2020 FDA advisory.

Experimental Cell Therapy

The FDA recently cleared a first-in-human stem-cell-derived therapy trial for focal epilepsy by Unixell.

This is still very early-stage research, but it represents movement toward:

• regenerative neurology
• targeted brain repair
• potentially disease-modifying epilepsy treatments instead of purely suppressive medications

Emerging Medications in Pipeline

Several drugs are still being watched closely in epilepsy:

• Xenon’s potassium channel seizure drug candidate
• BMB-101 for absence seizures and developmental epilepsies
• Continued fenfluramine data for Lennox-Gastaut syndrome

One disappointment:

• Takeda discontinued development of soticlestat after FDA review concerns.

Given your background and your advocacy work with epilepsy awareness, the AI + wearable monitoring direction is probably one of the biggest shifts happening right now. The field is increasingly moving toward:

• continuous physiologic monitoring
• predictive seizure modeling
• individualized seizure clustering analysis
• closed-loop intervention systems

rather than only “take medication and wait.”